Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials

Background: Immune checkpoint inhibitors (ICIs) have been a significant milestone for the treatment of advanced non-small cell lung cancer (NSCLC). However, the efficacy of ICIs can vary substantially between patients, with disparities in treatment outcomes being potentially driving by changes in th...

Full description

Bibliographic Details
Main Authors: Arkady T Manning-Bennett, Julie Cervesi, Pierre-Alain Bandinelli, Michael J Sorich, Ashley M Hopkins
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/11/2/528